Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Ombitasvir / Paritaprevir / Ritonavir und Dasabuvir -Nutzenbewertung gemäß § 35a SGB V des G-BA

Bedeutung der chronischen Hepatitis C ▼ Die Bedeutung der chronischen Hepatitis C Virusinfektion in Deutschland als eine der wichtigsten Ursachen für chronische Lebererkrankungen, der Leberzirrhose mit ihren Komplikationen, als Ursache für die Entwicklung des Leberzellkarzinoms und als Indikation zur Lebertransplantation [1] wurde in den Stellungnahmen der DGVS / DGIM bei den vorangegangenen Bewertungsverfahren zu Sofosbuvir, Simeprevir, Daclatasvir und Ledipasvir ausführlich erläutert.

[1]  T. Asselah,et al.  Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.

[2]  B. Conway,et al.  1012 MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir +/- Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With HCV Genotype 1 , 2015 .

[3]  T. Asselah,et al.  P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis , 2015 .

[4]  G. Dore,et al.  P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1 , 2015 .

[5]  P. Pang,et al.  O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks , 2015 .

[6]  X. Forns,et al.  An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.

[7]  J. Dufour,et al.  Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. , 2014, JAMA.

[8]  T. Berg,et al.  Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C , 2014, Zeitschrift für Gastroenterologie.

[9]  M. Manns,et al.  Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. , 2014, Journal of hepatology.

[10]  O. Weiland,et al.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.

[11]  V. de Lédinghen,et al.  Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. , 2014, Gastroenterology.

[12]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[13]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[14]  M. Buti,et al.  Strategies to manage hepatitis C virus (HCV) disease burden , 2014, Journal of viral hepatitis.

[15]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[16]  D. Samuel,et al.  Management of HCV transplant patients with triple therapy , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[17]  J. Albrecht,et al.  Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. , 2013, Journal of hepatology.

[18]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[19]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[20]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[21]  E. Schiff,et al.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.

[22]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[23]  M. Sherman,et al.  Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.